|
Toxicity and bioactivity evaluation of interferon alpha-2b conjugated with solid lipid nanoparticles
|
Delaram Doroud    1, Marjan Khatami2 , Nasim Rahmani3 , Maryam Shahali4 , Ariana Alavi5 , Mohammad Hossein Hedayati6 |
1- PhD in Pharmaceutical Sciences, Production & Research Complex, Tehran, Iran , d_doroud@yahoo.com
2- MsC in Biochemistry, Islamic Azad University, Science and Research Branch, Tehran, Iran
3- Pharm.D, Pharmaceutics and Drug Delivery Systems Laboratory, Production & Research Complex, Tehran, Iran
4- PhD in Molecular Genetics, Production & Research Complex, Tehran, Iran
5- BSc in Biotechnology, Pharmaceutics and Drug Delivery Systems Laboratory, Production & Research Complex, Tehran, Iran
6- PhD in Medicine Biotechnology, Production & Research Complex, Tehran, Iran |
|
|
Abstract: (918 Views) |
Background: Interferon (IFN) are small proteins that belong to the cytokine family and may interfere with viral infections and some cancers. There are many studies focused on the PEGylated interferon’s bioactivity. In this study, we used solid lipid nanoparticles (SLNs) to produce new drug formulations, with the aim of reducing costs, increasing effectiveness, and also reducing side effects, and the biological effects of the formulation and comparing the obtained results with the interferon alpha-2b and PEGylated interferon alpha-2b.
Materials and methods: In this study, we evaluateed the toxicity and bioactivity of three formulations: interferon alpha-2b, PEGylated interferon alpha-2b, and encapsulated interferon alpha-2b with solid lipid nanoparticles using the MTT method and cytopathic inhibition assay (CPE), respectively.
Results: The toxic effects of interferon encapsulated solid lipid nanoparticle (SLN-INF) was comparable with interferon and PEGylated interferon. In addition, empty solid lipid nanoparticles had no toxic effects on cells. The SLN-IFN showed higher bioactivity than the other samples tested (interferon alpha-2b, PEGylated interferon alpha-2b) and maintained its bioactivity over time.
Conclusion: The results of this study indicate that interferon alpha-2b conjugated with solid lipid nanoparticles is a capable formulation with sufficient bioactivity and acceptable toxicity as compared to PEGylated interferon and can be applied in clinical trials in future studies.
|
|
| Keywords: Interferon alpha-2b, Solid lipid nanoparticles (SLN), Bioactivity |
|
|
Full-Text [PDF 567 kb]
(573 Downloads)
|
Semi-pilot: Experimental |
Subject:
Pharmacology
Received: 2022/02/28 | Accepted: 2022/05/9 | Published: 2022/09/1
|
|
|
|
|
|
|
| References |
1. Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 2006;17:618-30. [ DOI:10.1021/bc050322y] 2. Bonjardim CA. Interferons (IFNs) are key cytokines in both innate and adaptive antiviral immune responses--and viruses counteract IFN action. Microbes Infect 2005;7:569-78. [ DOI:10.1016/j.micinf.2005.02.001] 3. Wadler S, Schwartz EL. New Advances in Interferon Therapy of Cancer. Oncologist 1997;2:254-67. [ DOI:10.1634/theoncologist.2-4-254] 4. Stanton GJ, Weigent DA, Fleischmann WR Jr, Dianzani F, Baron S. Interferon review. Invest Radiol 1987;22:259-73. [ DOI:10.1097/00004424-198703000-00017] 5. Dianzani F. Biological basis for the clinical use of interferon. Gut 1993;34: 74-76. [ DOI:10.1136/gut.34.2_Suppl.S74] 6. Goldstein D, Laszlo J. The role of interferon in cancer therapy: a current perspective. CA Cancer J Clin 1988;38:258-77. [ DOI:10.3322/canjclin.38.5.258] 7. Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 2006;17:618-30. [ DOI:10.1021/bc050322y] 8. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010;49:6288-308. [ DOI:10.1002/anie.200902672] 9. Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 2008;60:1638-49. [ DOI:10.1016/j.addr.2008.08.002] 10. Ghadiri M, Fatemi S, Vatanara A, Doroud D, Najafabadi AR, Darabi M, et al. Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. Int J Pharm 2012;424:128-37. [ DOI:10.1016/j.ijpharm.2011.12.037] 11. Heidari-Kharaji M, Taheri T, Doroud D, Habibzadeh S, Badirzadeh A, Rafati S. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model. Parasite Immunol 2016;38:599-608. [ DOI:10.1111/pim.12340] 12. Ramteke KH, Joshi SA, Dhole SN. Solid Lipid Nanoparticle: A Review. IOSR J Pharm 2012; 2:34-44. [ DOI:10.9790/3013-26103444] 13. Rassam, H. Allameh A, Eidi A, Alebouyeh M, Doroud D. Novel Formulation for Recombinant Streptokinase by Solid Lipid Nanoparticle: A Light at the End of the Tunnel. Arch Pharma Pract 2020;11:149-55. 14. Pieters R, Huismans DR, Leyva A, Veerman AJ. Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer 1989;59:217-20. [ DOI:10.1038/bjc.1989.44] 15. Mehrabi M, Mohammadpour Dounighi N, Rezayat Sorkhabadi SM, Doroud D, Amani A, Khoobi M, et al. Development and physicochemical, toxicity and immunogenicity assessments of recombinant hepatitis B surface antigen (rHBsAg) entrapped in chitosan and mannosylated chitosan nanoparticles: as a novel vaccine delivery system and adjuvant. Artif Cells Nanomed Biotechnol 2018;46:230-240. [ DOI:10.1080/21691401.2017.1417868] 16. Gilli F, De La Torre AL, Royce DB, Pachner AR. Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta. Int Immunopharmacol 2018;62:1-6. [ DOI:10.1016/j.intimp.2018.06.030] 17. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001;21:743-55. [ DOI:10.1089/107999001753124471] 18. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics 2018 ;10:57. [ DOI:10.3390/pharmaceutics10020057] 19. Palombo M, Deshmukh M, Myers D, Gao J, Szekely Z, Sinko PJ. Pharmaceutical and toxicological properties of engineered nanomaterials for drug delivery. Annu Rev Pharmacol Toxicol 2014;54:581-98. [ DOI:10.1146/annurev-pharmtox-010611-134615] 20. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007;59:478-90. [ DOI:10.1016/j.addr.2007.04.007] 21. Li S, Zhao B, Wang F, Wang M, Xie S, Wang S, et al. Yak interferon-alpha loaded solid lipid nanoparticles for controlled release. Res Vet Sci 2010;88:148-53. [ DOI:10.1016/j.rvsc.2009.06.010] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Doroud D, Khatami M, Rahmani N, Shahali M, Alavi A, Hedayati M H. Toxicity and bioactivity evaluation of interferon alpha-2b conjugated with solid lipid nanoparticles. MEDICAL SCIENCES 2022; 32 (3) :246-255 URL: http://tmuj.iautmu.ac.ir/article-1-1830-en.html
|
